Investigating What is the New Drug for OCD: Insights into Emerging Pharmacological Treatments
•
4 min read
While no single new drug has recently received widespread FDA approval specifically for obsessive-compulsive disorder (OCD) in 2025, a robust pipeline of investigational treatments is targeting refractory cases. For the approximately 40–60% of patients who do not respond adequately to first-line serotonin reuptake inhibitors (SSRIs), researchers are focusing on alternative neurobiological pathways, most notably the glutamate system.
